At BioProcess International European Summit, we sat down with Christian Eckermann, Head of Biopharma Austria and Member of the Biopharma Executive Committee at Boehringer Ingelheim, for an exclusive interview. We discussed next generation bioprocessing and facility implementation and the challenges that still need to be overcome to achieve it.
Watch the full interview above or here.
What are the biggest challenges that need to be overcome in bioprocessing?
CE: ‘One of the biggest challenges is…to be more effective in operation, but also in development; to have more effective high performance processes. Especially with the higher titres there will be a major press on downstream processing and there’s some innovation needed to improve the downstream part of it.
There are also some challenges with the new opportunities having new molecules, more designer molecules, moving away from the typical antibodies to biospecifics and other design formats. There is the development part to get to the market quickly, and the operations part with all the data there is a big opportunity and also a challenge to fully leverage that opportunity.’
Where do you see bioprocessing and facilities in 5 years? What are the biggest changes you expect to see?